Glaxosmithkline Pharmaceuticals Ltd

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Glaxosmithkline Pharmaceuticals Ltd has experienced a subtle shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook. Despite a modest day gain of 1.04%, the stock’s technical indicators present a complex picture, reflecting mixed signals across weekly and monthly timeframes. Investors and analysts are closely monitoring these developments as the mid-cap pharmaceutical player navigates a challenging market environment.

Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. The company’s recent downgrade from a Hold to a Sell rating by MarketsMOJO, accompanied by a Mojo Score of 43.0, reflects growing concerns over its near-term price performance amid a challenging market environment.

Despite a broader market rebound, Glaxosmithkline Pharmaceuticals Ltd has slipped to a fresh 52-week low of Rs 2,218 on 30 Mar 2026, extending its recent downward trajectory amid sector-wide volatility and company-specific valuation concerns.

Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s recent downgrade from a Hold to a Sell rating reflects deteriorating price action and weakening momentum, underscoring challenges ahead for investors in this mid-cap pharmaceutical stock.

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 March 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical parameters, reflecting a complex interplay of bullish and bearish signals. The stock’s recent price momentum, combined with mixed readings from key technical indicators such as MACD, RSI, and moving averages, suggests cautious investor sentiment amid broader sector challenges.

Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The stock’s recent price action and technical parameters suggest increasing downside pressure, raising concerns for investors amid a challenging market backdrop.

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 March 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Glaxosmithkline Pharmaceuticals Ltd (NSE: 793005) has experienced a notable shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the stock’s price action and technical indicators reveal a nuanced picture for investors navigating the Pharmaceuticals & Biotechnology sector.

Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in price momentum, reflected in a recent downgrade of its technical rating from Hold to Sell. The stock’s technical indicators reveal a transition towards bearish trends, with key metrics such as moving averages and Bollinger Bands signalling increased downside risk. This analysis delves into the technical parameters shaping the stock’s outlook and contextualises its performance against broader market benchmarks.

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 March 2026, providing investors with the latest insights into its performance and outlook.

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 February 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Glaxosmithkline Pharmaceuticals Ltd is rated Sell by MarketsMOJO. This rating was last updated on 20 Oct 2025, reflecting a shift from the previous Hold status. However, the analysis and financial metrics discussed here represent the stock’s current position as of 11 February 2026, providing investors with an up-to-date perspective on the company’s fundamentals and market performance.

Glaxosmithkline Pharmaceuticals Ltd recorded a robust intraday performance on 10 Feb 2026, surging 6.14% to touch a day’s high of Rs 2,632.9. The stock outperformed its sector and the broader market, reflecting heightened trading activity and notable volatility throughout the session.